Comparative Pharmacology
Head-to-head clinical analysis: CLORPRES versus DIUPRES 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLORPRES versus DIUPRES 250.
CLORPRES vs DIUPRES-250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CLORPRES is a combination of clonidine (alpha-2 adrenergic agonist that reduces sympathetic outflow) and chlorthalidone (thiazide diuretic that inhibits sodium reabsorption in distal tubules).
Diupres-250 is a combination of hydrochlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal convoluted tubule of the kidney, increasing excretion of sodium and water. Reserpine depletes catecholamines and serotonin from presynaptic nerve terminals by irreversibly binding to vesicular monoamine transporter (VMAT), leading to reduced sympathetic outflow and hypotension.
One tablet (clonidine 0.1 mg/chlorthalidone 15 mg) orally once or twice daily; maximum 0.6 mg clonidine/90 mg chlorthalidone daily.
1 tablet (containing 250 mg chlorothiazide and 0.125 mg reserpine) orally once daily, increased to 2 tablets daily if needed.
None Documented
None Documented
Terminal elimination half-life is 4-6 hours; may be prolonged in renal impairment, requiring dose adjustment.
Hydroflumethiazide: 6-18 hours (prolonged in renal impairment). Reserpine: 50-100 hours (biphasic; terminal phase).
Renal excretion accounts for approximately 50% of elimination, with 30% as unchanged drug and 20% as metabolites; biliary/fecal elimination accounts for about 10%.
Renal: approximately 50% of hydroflumethiazide is excreted unchanged in urine; reserpine is extensively metabolized with <1% excreted unchanged. Fecal: minimal.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination